This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Gilead’s Complera® Non-Inferior To Atripla® Among Treatment-Naïve HIV Patients

Stocks in this article: GILD

Virologic failure per snapshot algorithm was defined as patients failing to achieve viral load < 50 copies/mL at week 48, or discontinuing study drug prior to this time point due to lack of efficacy, or discontinuing study drug for other reasons and with last available viral load showing ≥ 50 copies/mL. Virologic failure rates for Complera and Atripla were, respectively, 5 percent and 3 percent for patients with viral load ≤ 100,000 copies/mL; 10 percent and 9 percent for patients with viral load > 100,000 to 500,000 copies/mL; and 25 percent and 16 percent for patients with viral load > 500,000 copies/mL.

Complera was approved in the United States in August 2011 and is indicated for use as a complete regimen for treatment-naïve adults with HIV-1 infection. Complera combines Gilead’s Truvada ® (emtricitabine and tenofovir disoproxil fumarate) with Janssen R&D Ireland’s rilpivirine (marketed as Edurant ®). In previous studies, more rilpivirine-treated patients with viral load > 100,000 copies/mL at the start of therapy experienced virologic failure compared to those with viral load < 100,000 copies/mL. Complera has Boxed Warnings of lactic acidosis/severe hepatomegaly with steatosis and post treatment acute exacerbation of hepatitis B; see below for important safety information.

Complera received marketing authorization from the European Commission as Eviplera in November 2011, becoming the first single tablet regimen approved for patients new to HIV therapy in Europe. In November 2012, Eviplera was added to European AIDS Clinical Society (EACS) treatment guidelines as a recommended regimen for treatment-naïve HIV patients.

About STaR

STaR (Study 110) is an ongoing, randomized (1:1), open-label Phase 3b study evaluating the efficacy and safety of Complera (n=394 treated) compared to Atripla (n=392 treated) among treatment-naïve HIV-positive adults with baseline HIV RNA levels ≥ 2,500 copies/mL. The primary objective of the study is to evaluate the non-inferiority, at a 12 percent margin, of Complera compared to Atripla in achieving HIV RNA levels < 50 copies/mL through 48 weeks of therapy, based on the FDA snapshot algorithm. Secondary endpoints include safety and efficacy of change from baseline in CD4 cell count at weeks 48 and 96 of therapy, and development of genotypic and phenotypic resistance at the time of virologic failure. Randomization was stratified by baseline HIV RNA levels (≤ or > 100,000 copies/mL).

2 of 7

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,796.09 +17.94 0.10%
S&P 500 2,064.50 +3.27 0.16%
NASDAQ 4,748.9970 +0.6010 0.01%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs